Science Explorer Interactive view Map
Company · Louisville · United States

NX PharmaGen (United States)

nxpharmagen.comROR OpenAlex
Research works
2
fractional, all time
Citations
75
32.2 per fractional work
Top-10% rate
0.0%
record average 16.5%
Open access
89%
world 28%

Not ranked overall: NX PharmaGen (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which research topics does NX PharmaGen (United States) publish most on?

By volume in 2022–2025: Cancer-related gene regulation, Lung Cancer Research Studies and Head and Neck Cancer Studies.

Cancer-related gene regu…0Cancer-related gene regulation: 0 fractional worksLung Cancer Research Stu…0Lung Cancer Research Studies: 0 fractional worksHead and Neck Cancer Stu…0Head and Neck Cancer Studies: 0 fractional works
Molecular BiologyOncologyOtorhinolaryngology

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Cancer-related gene regulation Molecular Biology 0 works
  2. 2 Lung Cancer Research Studies Oncology 0 works
  3. 3 Head and Neck Cancer Studies Otorhinolaryngology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available89.3%not open10.7%

World: 28% of research is openly available.

with international co-authors35.7%domestic only64.3%

World: 19% is written across borders.

How has NX PharmaGen (United States)'s research output changed?

199520002005201020152020

Other research institutions in Louisville

All research institutions in Louisville

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.